TD Cowen lowered the firm’s price target on Biogen (BIIB) to $200 from $275 and keeps a Buy rating on the shares. The firm reported a Q4 revenue and EPS beat but unfortunately 2025 guidance calling for a mid-single-digit revenue decline is below consensus.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen price target lowered to $157 from $192 at Morgan Stanley
- Biogen (BIIB) Q4 Results Make Analysts Feel Poorly About its Prospects
- Biogen price target lowered to $241 from $300 at H.C. Wainwright
- Cautious Outlook on Biogen Amid Declining MS Revenues and Uncertain Growth Prospects
- Biogen price target lowered to $265 from $298 at Canaccord